National Research Corporation logo
National Research Corporation NRC
$ 18.3 -18.08%
report update icon

Quarterly report 2026-Q1
added 05-06-2026

National Research Corporation Income Statement 2025-2008 | NRC

Brief overview of profit and loss at National Research Corporation

The overview follows changes across a five-year period. Revenue at National Research Corporation moved from $133 million in 2020 to $137 million in 2025. The total change was +3.1%, with a CAGR of approximately 0.6%. Revenue was effectively stagnant over the period.

The operating result measured by EBITDA moved from $43 million to $30.2 million, or −29.7%. EBITDA lagged revenue, showing weaker operating momentum. At the operating-margin level, the figure shifted from 32.3% to 22%. A lower EBITDA share weakens the quality of the result.

Net income changed from 37.3 million dollars to 11.6 million dollars (−68.9%). The decline reduces the quality of the financial trajectory.

Over the period, capitalization shifted from $1.1 billion to $315 million (−72.2%). The decline in value indicates softer investor confidence.

Overall conclusion

The results contain several connected negative signals. Caution is warranted because of lower investor confidence, a weaker final result and a softer top-line trend. The key question is whether sales can be converted into sustainable profit.

Annual Income Statement National Research Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

315 M 334 M 1.01 B 1.14 B 1.06 B 1.13 B 1.72 B 1.06 B 899 M 417 M 365 M 336 M 374 M - - - - -

Shares

22.4 M 23.7 M 24.5 M 24.9 M 25.4 M 25.2 M 24.8 M 27.1 M 24.3 M 24.2 M 24.2 M 24.2 M 24.1 M - - 6.64 M 6.64 M -

Historical Prices

14.1 14.1 41.1 45.7 41.6 45.1 66.8 38.3 35.5 16.2 13.4 12.1 13.1 - -

Net Income

11.6 M 24.8 M 31 M 31.8 M 37.5 M 37.3 M 32.4 M 30 M 22.9 M 20.5 M 17.6 M 18.2 M 15.5 M 15.1 M 11.6 M 11.6 M 8.49 M -

Revenue

137 M 143 M 149 M 152 M 148 M 133 M 128 M 120 M 118 M 109 M 102 M 98.8 M 92.6 M 86.4 M 75.8 M 63.4 M 57.7 M -

Gross Profit

- - - - - - 81.5 M 72.1 M 68.5 M 63.8 M 57.7 M 57.1 M 53.7 M 51 M 47.1 M - - -

Operating Income

22.6 M 35.2 M 40 M 46.5 M 50.3 M 42.7 M 43 M 35.3 M 34.2 M 31.2 M 26.4 M 28.3 M 24.8 M 22.7 M 18.7 M 13.9 M 13.7 M -

Interest Expense

-95 K 2.6 M 862 K 1.21 M 1.67 M 1.81 M 2.09 M 1.51 M 82 K 190 K 220 K 305 K 397 K 541 K 629 K 491 K 405 K -

EBITDA

30.2 M 41.2 M 45.9 M 46.7 M 50.6 M 43 M 48.6 M 40.7 M 38.8 M 35.4 M 30.6 M 32.1 M 28.5 M 27.4 M 23.8 M 18.6 M 17.5 M -

Operating Expenses

- - - - - - 38.5 M 36.8 M 34.3 M 32.6 M 31.3 M 28.8 M 28.9 M 28.2 M 28.4 M 49.5 M 44 M -

General and Administrative Expenses

54.8 M 44.9 M 46.6 M 42.7 M 39 M 34.4 M 33 M 31.4 M 29.7 M 28.4 M 27.2 M 25 M 25.2 M 23.5 M 23.3 M 20.2 M 16 M -

All numbers in USD currency

Quarterly Income Statement National Research Corporation

2026-Q1 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

21.8 M 22.1 M 22.7 M 23 M 23.1 M 23.7 M 23.9 M 23.9 M 24.2 M 24.6 M 24.6 M 24.6 M 24.6 M 24.7 M 25.1 M 25.3 M 25.4 M 25.4 M 25.4 M 25.4 M 25.4 M 25.2 M 25.1 M 25 M 24.9 M 24.8 M 24.8 M 24.8 M 24.8 M 24.8 M 24.8 M 24.8 M 20.9 M 20.9 M 20.9 M - - - - - - - - - - - - - - - - 6.89 M 6.87 M 6.79 M 6.75 M 6.72 M 6.72 M 6.68 M 6.66 M 6.65 M

Net Income

3.22 M 4.12 M -106 K 5.79 M - 5.69 M 6.18 M 6.36 M - 7.88 M 7.27 M 6.96 M - 8.3 M 8.32 M 8.54 M - 9.66 M 8.94 M 9.23 M - 9.58 M 7.72 M 11.8 M - 8.12 M 7.39 M 8.2 M - 6.99 M 7.95 M 7.31 M - 4.15 M 5.75 M 6.52 M - 4.73 M 4.56 M 5.51 M - 4.14 M 4.06 M 3.48 M - 4.55 M 4.05 M 5.45 M - 3.81 M 3.43 M 4.47 M - 3.58 M 3.94 M 3.85 M - 2.65 M 2.33 M 3.46 M

Revenue

34.8 M 34.6 M 34 M 33.6 M - 35.8 M 35 M 35.3 M - 37.9 M 36.2 M 36.5 M - 37.7 M 37.3 M 38.4 M - 37.8 M 36.4 M 35.5 M - 33.5 M 31.2 M 33.9 M - 32.5 M 31.4 M 31.5 M - 30 M 28 M 31 M - 29 M 28.4 M 30.3 M - 27 M 26.1 M 27.9 M - 25.2 M 24.5 M 26.3 M - 23.7 M 24 M 26 M - 22.4 M 22.4 M 24.9 M - 21.4 M 20.6 M 22.4 M - 18.5 M 18.3 M 19.8 M

Operating Income

5.57 M 7.74 M 1.59 M 8.6 M - 7.98 M 8.86 M 8.76 M - 9.96 M 9.36 M 9.02 M - 11.1 M 11.5 M 11.7 M - 13.1 M 12.2 M 12 M - 12 M 9.28 M 11.2 M - 10.2 M 10.1 M 10.7 M - 9.17 M 7.76 M 8.96 M - 7.12 M 8.45 M 9.98 M - 7.34 M 7.02 M 8.01 M - 6.55 M 6.36 M 5.83 M - 7.16 M 6.32 M 8.4 M - 6.03 M 5.53 M 7.22 M - 5.65 M 5.22 M 6.08 M - 4.19 M 3.83 M 5.7 M

Interest Expense

30 K 1.46 M 1.03 M 899 K - 706 K 555 K 605 K - -12 K -2 K 241 K - 288 K 318 K 317 K - 413 K 423 K 432 K - 451 K 450 K 465 K - 510 K 533 K 570 K - 544 K 439 K 8 K - 18 K 23 K 27 K - 38 K 36 K 85 K - 52 K 57 K 63 K - 76 K 78 K 81 K - 91 K 101 K 117 K - 134 K 140 K 142 K - 155 K 156 K 169 K

EBITDA

7.74 M 9.93 M 3.33 M 10.1 M - 9.53 M 10.4 M 10.2 M - 11.5 M 10.9 M 10.4 M - 12.4 M 12.8 M 13 M - 13.1 M 12.2 M 12 M - 13.9 M 10.7 M 12.6 M - 11.6 M 11.6 M 12.1 M - 10.6 M 9.08 M 10.2 M - 8.25 M 9.59 M 11.1 M - 8.42 M 8.11 M 8.97 M - 7.62 M 7.39 M 6.84 M - 8.11 M 7.24 M 9.34 M - 6.94 M 6.46 M 8.17 M - 6.8 M 6.43 M 7.32 M - 5.51 M 5.07 M 6.94 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - 21.3 M 20.8 M - 20.8 M 20.3 M 22.1 M - 21.8 M 20 M 20.3 M - 19.7 M 19.1 M 19.9 M - 18.7 M 18.1 M 20.4 M - 16.5 M 17.7 M 17.6 M - 16.4 M 16.8 M 17.7 M - 15.7 M 15.4 M 16.3 M - 14.4 M 14.5 M 14.1 M

General and Administrative Expenses

13.4 M 12.3 M 17.7 M 10.4 M - 11 M 11.2 M 11.2 M - 11.8 M 12 M 11.8 M - 10.8 M 10.7 M 10.6 M - 9.52 M 10 M 9.52 M - 7.95 M 8.85 M 8.75 M - 8.71 M 8.32 M 7.71 M - 7.68 M 7.94 M 7.87 M - 8.43 M 6.9 M 6.69 M - 7.14 M 7.27 M 7.36 M - 6.62 M 6.64 M 7.63 M - 5.8 M 5.98 M 6.37 M - 6.02 M 6.39 M 6.49 M - 5.82 M 5.57 M 6.15 M - 5.57 M 5.99 M 6.09 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company National Research Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Neogen Corporation Neogen Corporation
NEOG
$ 9.4 2.29 % $ 2.04 B usaUSA
Natera Natera
NTRA
$ 253.82 0.63 % $ 34.7 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Celcuity Celcuity
CELC
$ 83.26 0.97 % $ 3.89 B usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 26.1 2.19 % $ 24.7 B niderlandNiderland
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Personalis Personalis
PSNL
$ 11.73 -1.26 % $ 1.05 B usaUSA
Quidel Corporation Quidel Corporation
QDEL
$ 16.5 -1.02 % $ 695 M usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Co-Diagnostics Co-Diagnostics
CODX
$ 1.51 7.09 % $ 2.01 M usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Neuronetics Neuronetics
STIM
$ 1.82 -2.67 % $ 120 M usaUSA
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 35.41 -0.95 % $ 1.89 B usaUSA
NeoGenomics NeoGenomics
NEO
$ 15.27 13.96 % $ 1.96 B usaUSA
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Soleno Therapeutics Soleno Therapeutics
SLNO
- - $ 2.69 B usaUSA
Waters Corporation Waters Corporation
WAT
$ 379.48 -1.15 % $ 22.6 B usaUSA
Medpace Holdings Medpace Holdings
MEDP
$ 584.93 2.44 % $ 16.9 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 235.22 -0.31 % $ 26.1 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Exagen Exagen
XGN
$ 4.35 -2.25 % $ 93.8 M usaUSA
Biomerica Biomerica
BMRA
$ 1.59 -0.62 % $ 3.65 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
$ 7.1 -5.27 % $ 28.3 M israelIsrael
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 3.48 -1.14 % $ 113 K usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
DexCom DexCom
DXCM
$ 75.14 0.39 % $ 29.3 B usaUSA
OPKO Health OPKO Health
OPK
$ 1.37 -17.27 % $ 1.03 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 178.18 -1.14 % $ 14 B irlandaIrlanda
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA